

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Haberbosch, et al.  
Serial No. : DIVISIONAL APPL. OF 09/786,672  
Filed : CONCURRENTLY HERewith  
For : 3-DEAZAADENOSINE PREVENTS ATHEROSCLEROSIS  
AND GRAFT VASCULOPATHY  
Art Unit : 1614  
Examiner : P. G. Spivack

This is to certify that this correspondence is being sent by Express Mail in an envelope addressed to: MS: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 4, 2003.

Fani Malikouzakis



MS: Patent Applications  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

Sir:

Prior to examination, please amend the application as follows:

**IN THE CLAIMS**

Claims 1-17. (Cancelled)

Claim 18. (New) A stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which can be degraded to 3-deazaadenosine in the body under physiological conditions.

Claim 19. (New) The stent of claim 36, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.

Claim 20. (New) The stent of claim 36, wherein said 3-deazaadenosine or analog of 3-deazaadenosine is covalently bound to the stent.

Claim 21. (New) A method of preventing in-stent restenosis, reperfusion injuries or treating and preventing infectious and inflammatory coronary syndromes, dilated cardiomyopathy, viral myocarditis or infections by parasites by implanting the stent of claim 36 in a patient in need thereof.

Claim 22. (New) The method of claim 39, wherein the condition is in-stent restenosis.


**REMARKS**

Applicants have canceled claims 1-17 and added new claims 18-22.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By

  
James R. Crawford  
Reg. No. 39,155

666 Fifth Avenue  
New York, NY 10103  
(212) 318-3148